Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Study to Evaluate the Efficacy and Safety of PCSK9 Inhibitors in the Prevention of Chinese Heterozygous Familial Hypercholesterolemia

NCT04759534 is registered in ClinicalTrials.gov with Shenzhen People's Hospital as lead sponsor.

NCT NCT04759534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04759534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Study to Evaluate the Efficacy and Safety of PCSK9 Inhibitors in the Prevention of Chinese Heterozygous Familial Hypercholesterolemia
Lead sponsor
Shenzhen People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
September 10, 2020
Completion date
November 30, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy and safety, heterozygous familial hypercholesterolemia, pcsk9